Hansoh Pharma (03692): B7-H3 targeted antibody-drug conjugate HS-20093 used for breakthrough therapy in esophageal squamous cell carcinoma.
Hansom Pharmaceuticals (03692) announced that on May 9, 2026, the group's self-developed B7-H3-targeted antibody-drug conjugate (ADC) for injection HS-20093 has been approved by the China National Medical Products Administration (NMPA) as a breakthrough therapy. It is intended to be indicated for locally advanced or metastatic esophageal squamous cell carcinoma that is unresectable and has failed first-line treatment with platinum-based chemotherapy and immune checkpoint inhibitors (ICI).
Hansoh Pharma (03692) announced that on May 9, 2026, the group's self-developed B7-H3 targeted antibody-drug conjugate (ADC) injection HS-20093 has been approved by the National Medical Products Administration (NMPA) of China as a breakthrough therapy drug. It is proposed to be indicated for unresectable locally advanced or metastatic esophageal squamous cell carcinoma that has failed after previous first-line platinum-based chemotherapy and immune checkpoint inhibitor (ICI) therapy.
Related Articles
YIDU TECH (02158) once again receives a 9.08 million yuan AI order from a top hospital, deepening repeat purchases and verifying explosive revenue growth.
GMTEight List of A-share restricted sales and lifting restrictions | May 11th
BWI INT'L (02339) will resume trading on May 11th.
YIDU TECH (02158) once again receives a 9.08 million yuan AI order from a top hospital, deepening repeat purchases and verifying explosive revenue growth.
GMTEight List of A-share restricted sales and lifting restrictions | May 11th
BWI INT'L (02339) will resume trading on May 11th.
